廖曼,尚小珂,张长东,陈澍

• 1:华中科技大学同济医学院附属协和医院心脏大血管外科

摘要(Abstract)：

<正>卵圆孔是胎儿生命中正常的心房间交通孔,是胎儿循环的重要组成部分~([1])。卵圆孔是原发隔膜和继发隔膜之间的分隔孔,它允许腔静脉的血液通过卵圆孔绕过肺循环进入左心。随着出生时肺循环阻力的降低和左心房压力的增加,迫使原发隔的薄片压在卵圆孔的表面,原发隔与继发隔相互粘连、融合形

关键词(KeyWords)： 卵圆孔未闭;隐源性卒中;预防

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金（81570325）;; 湖北省卫健委创新基金（WJ2019M173）;; 国家重点研发计划（2016YFA0101100）

作者(Author): 廖曼,尚小珂,张长东,陈澍

参考文献(References)：

• [1]张宏伟，沈群山.偏头痛伴卵圆孔未闭患者介入封堵疗效观察.中国介入心脏病学杂志，2018, 26(11):627-631.
• [2] Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during thefirst 10 decades of life:An autopsy study of 965 normal hearts. Mayo Clin Proc, 1984,59(1):17-20.
• [3] Hara H, Virmani R, Ladich E, et al. Patent foramen ovale:Current pathology, pathophysiology, and clinical status. J Am Coll Cardiol, 2005, 46(9):1768-1776.
• [4] Saver JL, Mattle HP, Thaler D. Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke. Stroke,2018, 49(6):1541-1548.
• [5] Rana BS, Shapiro LM, Mccarthy KP, et al. Three-dimensional imaging of the atrial septum and patent foramen ovale anatomy:defining the morphological phenotypes of patent foramen ovale.Eur J Echocardiogr, 2010, 11(10):i19-i25.
• [6] Ho SY, McCarthy KP, Rigby ML. Morphological features pertinent to interventional closure of patent oval foramen. J Interv Cardiol, 2003, 16(1):33-38.
• [7] Tipoo Sultan FA, Allen S, Sharif M, et al. Paradoxical thrombus‘caught in the act’:Case report and review of literature. Am J Med, 2017, 130(1):e23-e25.
• [8] Onorato E, Casilli F. Influence of PFO anatomy on successful transcatheter closure. Interv Cardiol Clin, 2013, 2(1):51-84.
• [9] Bonati LH, Kessel-Schaefer A, Linka AZ, et al. Diffusionweighted imaging in stroke attributable to patent foramen ovale:significance of concomitant atrial septum aneurysm. Stroke,2006, 37(8):2030-2034.
• [10] Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke:Incidental or pathogenic? Stroke, 2009,40(7):2349-2355.
• [11] Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent f oramen ovale, atrial septal aneurysm, or both. N Engl J Med, 2001, 345(24):1740-1746.
• [12] Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology, 2013, 81(7):619-625.
• [13] Prefasi D, Martínez-Sánchez P, Fuentes B, et al. The utility of the RoPE score in cryptogenic stroke patients≤50 years in predicting a stroke-related patent foramen ovale. Int J Stroke,2016, 11(1):NP7-NP8.
• [14] Wessler BS, Kent DM, Thaler DE, et al. The RoPE score and right-to-left shunt severity by transcranial doppler in the CODICIA study. Cerebrovasc Dis, 2015, 40(1-2):52-58.
• [15] Thaler DE, Ruthazer R, Weimar C, et al. Recurrent stroke predictors diff er in medically treated patients with pathogenic vs.other PFOs. Neurology, 2014, 83(3):221-226.
• [16] Braemswig TB, Usnich T, Scheitz JF, et al. Early recurrent ischemic lesions in patients with cryptogenic stroke and patent foramen ovale:An Observational Study. Front Neurol, 2018, 9:996.
• [17] Hahn RT, Abraham T, Adams MS, et al. Guidelines for performing a comprehensive transesophageal echocardiographic examination:Recommendations f rom the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. Anesth Analg, 2014,118(1):21-68.
• [18] Mahmoud AN, Elgendy IY, Agarwal N, et al. Identification and quantification of patent foramen ovale-mediated shunts. Interv Cardiol Clin, 2017,6(4):495-504.
• [19] González-Alujas T, Evangelista A, Santamarina E, et al.Diagnosis and quantification of patent foramen ovale. Which is the reference technique? Simultaneous study with transcranial doppler, transthoracic and transesophageal echocardiography.Rev Esp Cardiol, 2011, 64(2):133-139.
• [20] Mojadidi MK, Roberts SC, Winoker JS, et al. Accuracy of transcranial doppler for the diagnosis of intracardiac right-to-left shunt:A bivariate meta-analysis of prospective studies. JACC Cardiovasc Imaging, 2014, 7(3):236-250.
• [21] Tobe J, Bogiatzi C, Munoz C, et al. Transcranial Doppler is complementary to echocardiography for detection and risk stratification of patent foramen ovale. Can J Cardiol, 2016, 32(8):986.e9-e16.
• [22] Kasner SE, Swaminathan B, Lavados P, et al. Rivaroxaban or aspirin f or patent f oramen ovale and embolic stroke of undetermined source:a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol, 2018, 17(12):1053-1060.
• [23] Mas J, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. Antiplatelets after stroke. N Engl J Med, 2017, 377(11):1011-1021.
• [24] Hornung M, Bertog SC, Franke J, et al. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur Heart J,2013, 34(43):3362-3369.
• [25] Schwerzmann M, Windecker S, Wahl A, et al. Percutaneous closure of patent foramen ovale:impact of device design on safety and efficacy. Heart, 2004, 90(2):186-190.
• [26] Tsivgoulis G, Katsanos AH, Mavridis D, et al. Percutaneous patent foramen ovale closure for secondary stroke prevention:Network Meta-analysis. Neurology, 2018, 91(1):e8-e18.
• [27] Pristipino C, Sievert H, D’Ascenzo F, et al. European position paper on the management of patients with patent foramen ovale.General approach and left circulation thromboembolism. Eur Heart J, 2019, 40(38):3182-3195.
• [28] Elgendy AY, Elgendy IY, Mojadidi MK, et al. New-onset atrialfibrillation following percutaneous patent foramen ovale closure:A systematic review and meta-analysis of randomised trials.EuroIntervention, 2019, 14(17):1788-1790.
• [29] Bridges ND, Hellenbrand W, Latson L, et al. Transcatheter closure of patent foramen ovale af ter presumed paradoxical embolism. Circulation, 1992, 86(6):1902-1908.
• [30] Khairy Paul, O’Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli. Ann Intern Med, 2003, 139(9):753-760.
• [31] Windecker S, Wahl A, Nedeltchev K, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol,2004, 44(4):750-758.
• [32] Furlan AJ, Reisman M, Massaro J,et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med, 2012, 366(11):991-999.
• [33] Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med,2013, 368(12):1083-1091.
• [34] Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med, 2013, 368(12):1092-1100.
• [35] Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med, 2017,377(11):1022-1032.
• [36] S?ndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med,2017,377(11):1033-1042.
• [37] Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and highrisk patent foramen ovale:The DEFENSE-PFO trial. J Am Coll Cardiol, 2018, 71(20):2335-2342.
• [38] Rosa SD, Sievert H, Sabatino J, et al. Percutaneous closure versus medical treatment in stroke patients with patent foramen ovale:A systematic review and Meta-analysis. Ann Intern Med,2018, 168(5):343-350.
• [39] Shah R, Nayyar M, Jovin IS, et al. Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke. Ann Intern Med, 2018,168(5):335-342.
• [40] Abdelghani M, EI-Shedougy SAO, Nassif M, et al. Management of patients with patent foramen ovale and cryptogenic stroke:An Update. Cardiology, 2019, 143(1):62-72.
• [41] Hart RG, Catanese L, Perera KS, et al. Embolic stroke of undetermined source:A systematic review and clinical update.Stroke, 2017, 48(4):867-872.
• [42] Ntaios G, Papavasileiou V, Sagris D, et al. Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack. Stroke, 2018, 49(2):412-418.
• [43] Abaci A, Unlu S, Alsancak Y, et al. Short and long term complications of device closure of atrial septal defect and patent foramen ovale:Meta-analysis of 28,142 patients f rom 203studies. Catheter Cardiovasc Interv, 2013, 82(7):1123-1138.
• [44] Wiktor DM, Carroll JD. The case for selective patent foramen ovale closure after cryptogenic stroke. Circ Cardiovasc Interv,2018, 11(3):e004152.
• [45] Alkhouli M, Sievert H, Holmes DR. Patent foramen ovale closure for secondary stroke prevention. Eur Heart J, 2019, 40(28):2339-2350.
• [46]何璐，张玉顺.单中心1336例经导管封堵卵圆孔未闭患者主要并发症回顾性分析.中国介入心脏病学杂志，2019, 27(6):309-314.